CHAPTER 1 INTRODUCTION

1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology

1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Analyst Tools and Models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO Perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Key Findings

3.2.1 Top Impacting Factors
3.2.2 Top Investment Pockets

3.3 Porters Five Force Analysis
3.4 Drivers

3.4.1 Growing Number of patients undergoing Chemotherapy
3.4.2 Growing research and development efforts in order to discover a universal antiemetic therapy
3.4.3 Introduction of novel delivery methods to improve patient compliance.
3.4.4 Advancements in technology to discover new potential drug targets

3.5 Restrains

3.5.1 Increasing side effects of CINV drugs
3.5.2 High cost associated with the new drug discovery and in developing regions.

3.6 Opportunities

3.6.1 Efficacy of combination therapy is expected to improve.
3.6.2 Improved quality of life for patients with cancer.

3.7 Market Trends

CHAPTER 4 CINV MARKET BY PATIENT POOL

4.1 Overview
4.2 Netupitant-Palonosetron FDC

4.2.1 Key market trends
4.2.2 Key growth factors & opportunities
4.2.3 Market size & forecasts

4.3 Aloxi (palonosetron)

4.3.1 Key market trends
4.3.2 Key growth factors & opportunities
4.3.3 Market size & forecasts

4.4 Kytril Generic (Granisetron)

4.4.1 Key market trends
4.4.2 Key growth factors & opportunities
4.4.3 Market size & forecasts

4.5 Emend (aprepitant)

4.5.1 Key market trends
4.5.2 Key growth factors & opportunities
4.5.3 Market size & forecasts

CHAPTER 5 CINV MARKET BY GEOGRAPHY

5.1 North America

5.1.1 Key Market Trends
5.1.2 Key Growth Factors and Opportunities
5.1.3 Market Size and Forecast

5.2 Europe

5.2.1 Key Market Trends
5.2.2 Key Growth Factors and Opportunities
5.2.3 Market Size and Forecast

5.3 Asia-Pacific

5.3.1 Key Market Trends
5.3.2 Key Growth Factors and Opportunities
5.3.3 Market Size and Forecast

5.4 Latin America, Middle East and Africa (LAMEA)

5.4.1 Key Market Trends
5.4.2 Key Growth Factors and Opportunities
5.4.3 Market Size and Forecast

CHAPTER6 COMPANY PROFILES

6.1 Helsinn Holding S.A.

6.1.1 Company Overview
6.1.2 Key Strategies and Developments
6.1.3 SWOT Analysis

6.2 Heron Therapeutics, Inc.

6.2.1 Company Overview
6.2.2 Business Performance
6.2.3 Key Strategies and Developments
6.2.4 SWOT Analysis

6.3 Merck & Co., Inc

6.3.1 Company Overview
6.3.2 Business Performance
6.3.3 Key Strategies and Developments
6.3.4 SWOT Analysis

6.4 GlaxoSmithKline plc

6.4.1 Company Overview
6.4.2 Business Performance
6.4.3 Key Strategies and Developments
6.4.4 Key Strategies and Developments
6.4.5 SWOT Analysis

6.5 Cadila Pharmaceuticals Limited

6.5.1 Company Overview
6.5.2 Business Performance
6.5.3 Key Strategies and Developments
6.5.4 Key Strategies and Developments
6.5.5 SWOT Analysis

6.6 Amneal Pharmaceuticals

6.6.1 Company Overview
6.6.2 Business Performance
6.6.3 Key Strategies and Developments
6.6.4 Key Strategies and Developments
6.6.5 SWOT Analysis

6.7 Kyowa Kirin, Inc.

6.7.1 Company Overview
6.7.2 Business Performance
6.7.3 Key Strategies and Developments
6.7.4 Key Strategies and Developments
6.7.5 SWOT Analysis

6.8 Acacia Pharma

6.8.1 Company Overview
6.8.2 Business Performance
6.8.3 Key Strategies and Developments
6.8.4 Key Strategies and Developments
6.8.5 SWOT Analysis

6.9 Insys Therapeutics, Inc

6.9.1 Company Overview
6.9.2 Business Performance
6.9.3 Key Strategies and Developments
6.9.4 Key Strategies and Developments
6.9.5 SWOT Analysis

6.10 Tesaro, Inc.

6.10.1 Company Overview
6.10.2 Business Performance
6.10.3 Key Strategies and Developments
6.10.4 Key Strategies and Developments
6.10.5 SWOT Analysis

*Details on financial performance, strategic moves and developments and SWOT analysis may not be captured for unlisted companies.

List of Figures

FIG. 1 TOP IMPACTING FACTORS
FIG. 2 TOP INVESTMENT POCKETS
FIG. 3 PORTERS FIVE FORCES ANALYSIS OF LITHIUM-ION BATTERY MARKET
FIG. 4 WORLD CINV MARKET BY TYPE, 2015(PIE CHART OF GLOBAL NUMBERS BY TYPE)
FIG. 5 WORLD CINV MARKET BY GEOGRAPHY, 2015(PIE CHART OF GLOBAL NUMBERS BY GEOGRAPHY)
FIG. 6 NET SALES OF HERON THERAPEUTICS, INC., 2013-2015 ($MILLION)
FIG. 7 NET SALES OF HERON THERAPEUTICS, INC., BY SEGMENT (%), 2015
FIG. 8 NET SALES OF HERON THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015
FIG. 10 NET SALES OF MERCK & CO., INC, 2013-2015 ($MILLION)
FIG. 11 NET SALES OF MERCK & CO., INC., BY GEOGRAPHY (%), 2015
FIG. 11 NET SALES OF MERCK & CO., INC., BY SEGMENT (%), 2015
FIG. 12 NET SALES OF GLAXOSMITHKLINE PLC ., 2013-2015 ($MILLION)
FIG. 13 NET SALES OF GLAXOSMITHKLINE PLC, BY SEGMENT (%), 2015
FIG. 14 NET SALES OF GLAXOSMITHKLINE PLC, BY GEOGRAPHY (%), 2015
FIG. 18 NET SALES OF KYOWA KIRIN, INC., 2013-2015 ($MILLION)
FIG. 13 NET SALES OF KYOWA KIRIN, INC., BY SEGMENT (%), 2015
FIG. 14 NET SALES OF KYOWA KIRIN, INC., BY GEOGRAPHY (%), 2015
FIG. 22 REVENUE OF INSYS THERAPEUTICS, INC., 2013-2015 ($MILLION)
FIG. 13 NET SALES OF INSYS THERAPEUTICS, INC., BY SEGMENT (%), 2015
FIG. 14 NET SALES OF INSYS THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015
FIG. 22 REVENUE OF TESARO, INC, 2013-2015 ($MILLION)
FIG. 13 NET SALES OF TESARO, INC, BY SEGMENT (%), 2015
FIG. 14 NET SALES OF TESARO, INC, BY GEOGRAPHY (%), 2015

List of Tables

TABLE 1 WORLD CINV MARKET BY PATIENT POOL(NETUPITANT-PALONOSETRON FDC) MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 2 WORLD CINV MARKET BY PATIENT POOL( ALOXI) , ($MILLION), GROWTH (%)2014-2022
TABLE 3 WORLD CINV MARKET BY PATIENT POOL(KYTRIL GENERIC ) , ($MILLION), GROWTH (%)2014-2022
TABLE 4 WORLD CINV MARKET BY PATIENT POOL(EMEND ) , ($MILLION), GROWTH (%)2014-2022
TABLE 5 NORTH AMERICA CINV MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 6 EUROPE CINV MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 7 ASIA CINV MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 8 LAMEA CINV MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 9 HELSINN HOLDING S.A.COMPANY SNAPSHOT
TABLE 9 HELSINN HOLDING S.A.OPERATING SEGMENTS
TABLE 10 HERON THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 11 HERON THERAPEUTICS, INC.OPERATING SEGMENTS
TABLE 12 MERCK & CO., INC. COMPANY SNAPSHOT
TABLE 13 MERCK & CO., INC.OPERATING SEGMENTS
TABLE 14 GLAXOSMITHKLINE PLC COMPANY SNAPSHOT
TABLE 15 GLAXOSMITHKLINE PLC OPERATING SEGMENTS
TABLE 16 CADILA PHARMACEUTICALS LIMITED COMPANY SNAPSHOT
TABLE 17 CADILA PHARMACEUTICALS LIMITED OPERATING SEGMENTS
TABLE 18 AMNEAL PHARMACEUTICALS COMPANY SNAPSHOT
TABLE 19 AMNEAL PHARMACEUTICALS OPERATING SEGMENTS
TABLE 20 KYOWA KIRIN, INC. COMPANY SNAPSHOT
TABLE 21 KYOWA KIRIN, INC. OPERATING SEGMENTS
TABLE 22 ACACIA PHARMA COMPANY SNAPSHOT
TABLE 23 ACACIA PHARMA OPERATING SEGMENTS
TABLE 24 INSYS THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 25 INSYS THERAPEUTICS, INC. OPERATING SEGMENTS
TABLE 26 TESARO, INC. COMPANY SNAPSHOT
TABLE 27 TESARO, INC. OPERATING SEGMENTS

Chemotherapy-induced nausea and vomiting (CINV) drugs market experiences growth due to increase in number of patients undergoing chemotherapy and increased uptake of low toxicity targeted treatments. Some of the key drugs in the market are Akynzeo, Emend, Aloxi, Zofran, Kytril and SUSTOL and Rolapitant. At present, pharmaceutical companies have prioritized investment in R&D of CINV drugs for driving their profit margins and sustain the use of chemotherapeutic drugs.

Granisetron transdermal patch with the trade name Sancuso was approved by the US FDA. It is manufactured by 3M Drug Delivery Systems. Granisetron is a selective inhibitor of type 3 serotonergic (5-HT3) receptors. It has little or no affinity for other serotonin receptors, including 5-HT 1, 5-HT 1A, 5-HT, or 5-HT 2. The cancer population living in the developing economies of LAMEA and Asia-Pacific are adopting novel CINV drug delivery methods such as combination therapies and transdermal patches to minimize the side effects of chemotherapeutic drugs. CINV market in North America generates the largest share of global CINV drugs market, followed by Europe and Asia-Pacific. The demand for CINV drugs market in Asia-Pacific market is expected to post the fastest growth for CINV drugs market.

The key players in the global chemotherapy-induced nausea and vomiting drugs are GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc.